Q2 2023

Filed Aug 3, 2023 · 10-Q · 34 days after period end · 0000950170-23-037943

Q2 2023 · 10-Q

Revenue

$0.00

no prior Q2 2022 on file

Net Income

-$44.62M

N/M vs Q2 2022

EPS Diluted

-$0.64

N/M vs Q2 2022

Operating Income-$49,678,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	$0.00	—	$379.00K	$379.00K
Net Income	-$44.62M	-$37.57M	-$22.91M	-$17.06M
EPS Diluted	-$0.64	-$0.62	-$0.44	-$0.42

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR